Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article
Author Archives for Adeline Chauvigné
Valneva reports further positive phase 3 immunogenicity and the first heterologous booster tesults for its inactivated, adjuvanted COVID-19 vaccine VLA2001
1 November 2025Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article
New member | Rouen Normandy University
Rouen Normandy University, which employs more than 2500 persons, is a multidisciplinary university, hosting approximately 35,000 students, nearly a quarter... View Article
New member | Rouen Normandy University
1 November 2025Rouen Normandy University, which employs more than 2500 persons, is a multidisciplinary university, hosting approximately 35,000 students, nearly a quarter... View Article
New member | University of Orléans
The University of Orléans is characterized by its multidisciplinary nature. It has 3 Training and Research Units, 1 university engineering... View Article
New member | University of Orléans
1 November 2025The University of Orléans is characterized by its multidisciplinary nature. It has 3 Training and Research Units, 1 university engineering... View Article
Valneva confirms WHO recommendations for its inactivated COVID-19 vaccine
Valneva, a specialty vaccine company, confirms that the World Health Organization (WHO) has issued recommendations for use of the Company’s... View Article
Valneva confirms WHO recommendations for its inactivated COVID-19 vaccine
1 November 2025Valneva, a specialty vaccine company, confirms that the World Health Organization (WHO) has issued recommendations for use of the Company’s... View Article
Framatome announces investment in Global Morpho Pharma for nuclear medicine development
Framatome announced that it acquired a minority stake in Global Morpho Pharma. With this investment, Framatome strengthens its activities serving... View Article
Framatome announces investment in Global Morpho Pharma for nuclear medicine development
1 November 2025Framatome announced that it acquired a minority stake in Global Morpho Pharma. With this investment, Framatome strengthens its activities serving... View Article
European Commission approves purchase agreement amendment for Valneva’s inactivated COVID-19 vaccine
European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Valneva, a specialty vaccine company,... View Article
European Commission approves purchase agreement amendment for Valneva’s inactivated COVID-19 vaccine
1 November 2025European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Valneva, a specialty vaccine company,... View Article
Focus on the Atlanpole Biotherapies 2022 General Assembly
ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY. In addition to taking stock... View Article
Focus on the Atlanpole Biotherapies 2022 General Assembly
1 November 2025ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY. In addition to taking stock... View Article
OSE Immunotherapeutics appoints Alexis Vandier as Chief Executive Officer
OSE Immunotherapeutics is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings... View Article
OSE Immunotherapeutics appoints Alexis Vandier as Chief Executive Officer
1 November 2025OSE Immunotherapeutics is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
1 November 2025Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
VitaDX and MEDIPATH collaborate to deploy VisioCyt®, an innovative solution for the early diagnosis of bladder cancer
VitaDX – a deeptech healthcare company pioneering the use of artificial intelligence and image processing in cytology – announces its... View Article
VitaDX and MEDIPATH collaborate to deploy VisioCyt®, an innovative solution for the early diagnosis of bladder cancer
1 November 2025VitaDX – a deeptech healthcare company pioneering the use of artificial intelligence and image processing in cytology – announces its... View Article